Archive by category | - Martin Partl

CEITEC grows in Brno

CEITEC grows in Brno

The Central European Institute of Technology (CEITEC) is establishing an R&D infrastructure project that eventually will cost $300 million in Brno within the next three years. The money for the European centre of scientific excellence comes from the Operational Programme Research and Development for innovation of the European Structural funds. The institute, which will interconnect life sciences and technical fields, will be used by up to 600 scientists and by over 1,200 students, and also by Czech and foreign companies. It will also help the existing basic and applied research in the entire Czech Republic to achieve top levels.  Read more

Czech Republic´s International Cooperation

Czech Republic´s International Cooperation

Few in the healthcare industry have not heard about Gilead Sciences’ success against HIV/AIDS and hepatitis B. Viread and Hepsera, the two flagship drugs for treating these conditions, were first conceived by Czech scientists in the Prague-based Institute of Organic Chemistry and Biochemistry, led by professor Antonin Holy. They discovered tenofovir disoproxil fumarate, the active ingredient in Viread, which is used to treat HIV/AIDS. Likewise, the hepatitis B drug Hepsera produced by Gilead Sciences is based on a compound discovered in Prof. Holy’s laboratory in Prague. As a result of previous cooperation between the institute and Gilead, Holy signed a contract with Gilead, offering his discoveries in basic research. Gilead took his work and further developed it.  Read more